A similar trend was observed for CK7+ epithelial/tumor cells, with TUNEL positivity rising from approximately 8% in the control group to 18% with bevacizumab and 35% with anlotinib, and further to approximately 58% with the combination treatment. Here, KRT7 is linked to neoplasm.